Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ipsen
Ipsen
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
Flag link:
6 Drugs Approved Despite Failed Trials or Minimal Data
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Exelixis
Ipsen
Carbometyx
prostate cancer
Flag link:
FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease
FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease
BioSpace
Ipsen
palovarotene
FDA
Sohonos
fibrodysplasia ossificans progressiva
Flag link:
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Flag link:
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Flag link:
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
Flag link:
FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP
FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP
Globe Newswire
FDA
Ipsen
palovarotene
FOP
fibrodysplasia ossificans progressiva
Flag link:
FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm
FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm
BioSpace
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva
Flag link:
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
Fierce Pharma
Ipsen
Bylvay
Albireo Pharma
M&A
FDA
liver disease
Flag link:
Biotech M&A is picking back up - here are the latest deals
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Pfizer's fortunes overshadow first-quarter dealmaking
Pfizer's fortunes overshadow first-quarter dealmaking
EP Vantage
M&A
Pfizer
Seagen
Sanofi
Provention Bio
AstraZeneca
CinCor
Chiesi
Amryt
Ipsen
Albireo
Flag link:
FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on
FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on
Fierce Biotech
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva
Flag link:
Ipsen reports positive data from pancreatic ductal adenocarcinoma trial
Ipsen reports positive data from pancreatic ductal adenocarcinoma trial
Clinical Trials Arena
Ipsen
Onivyde
metastatic pancreatic cancer
pancreatic cancer
clinical trials
Flag link:
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Fierce Biotech
Ipsen
IRLAB
clinical trials
Parkinson's Disease
mesdopetam
Flag link:
Biopharma’s bolt-on bonanza is set to continue
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Flag link:
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
BioPharma Dive
JPMHC 2023
M&A
AstraZeneca
CinCor
Ipsen
Albireo
Chiesi Farmaceutici
Amryt Pharma
Flag link:
Ipsen's rare disease candidate rejected after mounting setbacks, delays
Ipsen's rare disease candidate rejected after mounting setbacks, delays
Fierce Biotech
Ipsen
FDA
palovarotene
Flag link:
Pages
1
2
3
4
next ›
last »